FISH技术在多发性骨髓瘤中的优势与不足
Advantages and Shortcomings of FISH Tech-nology in Multiple Myeloma
DOI: 10.12677/ACM.2022.12111443, PDF,   
作者: 赵子澜：青海大学研究生院，青海 西宁 ；罗 伟*：青海大学附属医院血液科，青海 西宁
关键词: 多发性骨髓瘤；荧光原位杂交技术；Multiple Myeloma； Fluorescence in Situ Hybridization Technique
摘要: 多发性骨髓瘤是血液疾病中较为常见的恶性肿瘤，随着时间的发展，我们愈发发现遗传学技术对此疾病的影响。荧光原位杂交(FISH)是一种基因检测技术，目前已应用在了多发性骨髓瘤的检测中，并且体现出其自身的优势，但它本身也有一些不足之处。本文就FISH技术在多发性骨髓瘤中的优势与不足进行综述。
Abstract: Multiple myeloma is one of the most common hematologic malignancies. With the development of time, we are increasingly discovering the impact of genetic techniques on this disease. Fluorescence in situ hybridization (FISH) is a genetic detection technology, which has been applied in the detec-tion of multiple myeloma, and shows its own advantages, but it also has some shortcomings. This article reviews the advantages and disadvantages of FISH in multiple myeloma.
文章引用：赵子澜, 罗伟. FISH技术在多发性骨髓瘤中的优势与不足[J]. 临床医学进展, 2022, 12(11): 10008-10011. https://doi.org/10.12677/ACM.2022.12111443

参考文献

[1] Rajkumar, S., Dimopoulos, M., Palumbo, A., et al. (2014) International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma. The Lancet Oncology, 15, e538-e548. [Google Scholar] [CrossRef] 
[2] Rajkumar, S.V. (2020) Multiple Myeloma: 2020 Update on Diagnosis, Risk-Stratification and Management. American Journal of Hematology, 95, 548-567. [Google Scholar] [CrossRef] [PubMed]
[3] Stella, F., Pedrazzini, E., Agazzoni, M., Ballester, O. and Slavutsky, I. (2015) Cytogenetic Alterations in Multiple Myeloma: Prognostic Significance and the Choice of Frontline Therapy. Cancer In-vestigation, 33, 496-504. [Google Scholar] [CrossRef] [PubMed]
[4] 胡凯, 王晶, 朱明霞, 王艳芳, 克晓燕. 不同预后分层的多发性骨髓瘤患者免疫表型特征分析[J]. 中国实验血液学杂志, 2014, 22(6): 1624-1627.
[5] Mikhael, J., Dingli, D., Roy, V., et al. (2013) Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratifica-tion of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. Mayo Clinic Proceedings, 88, 360-376. [Google Scholar] [CrossRef] [PubMed]
[6] Greipp, P., San Miguel, J., Durie, B., et al. (2005) In-ternational Staging System for Multiple Myeloma. Journal of Clinical Oncology, 23, 3412-3420. [Google Scholar] [CrossRef] 
[7] Liebisch, P. and Döhner, H. (2006) Cytogenetics and Molecular Cytogenetics in Multiple Myeloma. European Journal of Cancer, 42, 1520-1529. [Google Scholar] [CrossRef] [PubMed]
[8] Rajkumar, S.V., Fonseca, R., Dewald, G.W., et al. (1999) Cytoge-netic Abnormalities Correlate with the Plasma Cell Labeling Index and Extent of Bone Marrow Involvement in Myeloma. Cancer Genetics, 113, 73-77. [Google Scholar] [CrossRef] 
[9] Chen, L., Li, J., Xu, W., et al. (2007) Molecular Cytogenetic Aberrations in Patients with Multiple Myeloma Studied by Interphase Fluorescence in Situ Hybridization. Experimental Oncology, 29, 116-120.
[10] 王存邦, 吴静, 杨珂, 苏淼, 张海英, 潘耀柱, 吴涛, 葸瑞, 白海. 多发性骨髓瘤遗传学异常的回顾性分析[J]. 中国实验血液学杂志, 2018, 26(6): 1681-1687.
[11] Flactif, M., Zandecki, M., Laï, J., et al. (1995) Interphase Fluorescence in Situ Hybridization (FISH) as a Powerful Tool for the Detection of Aneuploidy in Multiple Myeloma. Leukemia, 9, 2109-2114.
[12] Avet-Loiseau, H., Attal, M., Campion, L., et al. (2012) Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q Gains] Play a Major Role in Defining Long-Term Survival. Journal of Clinical Oncology, 30, 1949-1952. [Google Scholar] [CrossRef] 
[13] Shaughnessy, J., Jacobson, J., Sawyer, J., et al. (2003) Continuous Absence of Metaphase-Defined Cytogenetic Abnormalities, Especially of Chromosome 13 and Hypodiploidy, Ensures Long-Term Survival in Multiple Myeloma Treated with Total Therapy I: Interpretation in the Context of Global Gene Ex-pression. Blood, 101, 3849-3856. [Google Scholar] [CrossRef] [PubMed]
[14] 杨璐璐, 聂玉, 刘欣, 汪健, 王晓秋, 王志华, 郑昌成, 王兴兵, 朱小玉, 朱薇波, 孙自敏, 蔡晓燕, 吴竞生. 免疫组织化学联合荧光原位杂交技术检测多发性骨髓瘤分子细胞遗传学异常[J]. 中华临床医师杂志(电子版), 2013, 7(8): 3345-3350.
[15] Terpos, E., Zamagni, E., Lentzsch, S., et al. (2021) Treatment of Multiple Myeloma-Related Bone Disease: Recommendations from the Bone Working Group of the International Myeloma Working Group. The Lancet Oncology, 22, e119-e130. [Google Scholar] [CrossRef] 
[16] 梅建刚, 李翰卿, 曹红琴, 邵靓婧, 翟勇平. CD138磁珠分选结合间期荧光原位杂交在浆细胞病遗传学诊断中的应用价值[J]. 中国实验血液学杂志, 2016, 24(5): 1437-1442.
[17] 安刚, 李承文, 李倩, 易树华, 刘旭平, 徐燕, 李增军, 齐军元, 邹德慧, 邱录贵. 免疫磁珠分选对荧光原位杂交检测多发性骨髓瘤细胞遗传学异常的影响[J]. 中国实验血液学杂志, 2011, 19(1): 54-58.
[18] 李玉滨. 209例多发性骨髓瘤患者细胞遗传学异常回顾性分析[D]: [硕士学位论文]. 济南: 山东大学, 2021.
[19] 吕佳, 贺扬欣, 王锦程, 孙吉平, 解立怡, 贺鹏程, 陈颖. 多发性骨髓瘤伴肾损害患者肾脏病理及细胞遗传学检查的回顾性分析[J]. 中国实验血液学杂志, 2020, 28(4): 1272-1277.
[20] Hagen, P., Zhang, J. and Barton, K. (2020) High-Risk Disease in Newly Diagnosed Multiple Myeloma: Beyond the R-ISS and IMWG Definitions. Blood Cancer Journal, 12, Article No. 83. [Google Scholar] [CrossRef] [PubMed]
[21] Goldsmith, S., Fiala, M., Dukeman, J., et al. (2019) Next Generation Sequencing-Based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study. Clinical Lymphoma, Myeloma and Leukemia, 19, 285-289. [Google Scholar] [CrossRef] [PubMed]

为你推荐